Methylprednisolone suleptanate

Drug Profile

Methylprednisolone suleptanate

Alternative Names: Medrosol; PNU 67590A; Promedrol; U 67590A

Latest Information Update: 05 May 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antiasthmatics; Corticosteroids
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Lupus nephritis; Nephrotic syndrome; Renal transplant rejection; Shock; Spinal cord injuries

Most Recent Events

  • 05 May 2004 No development reported - Phase-II for Lupus nephritis (Injection)
  • 05 May 2004 No development reported - Phase-III for Asthma in Japan (Injection)
  • 05 May 2004 No development reported - Preclinical for Spinal cord injuries (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top